Advertisement

Research Article Free access | 10.1172/JCI119565

Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.

N W Boonmark, X J Lou, Z J Yang, K Schwartz, J L Zhang, E M Rubin, and R M Lawn

Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, California 94305-5246, USA.

Find articles by Boonmark, N. in: JCI | PubMed | Google Scholar

Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, California 94305-5246, USA.

Find articles by Lou, X. in: JCI | PubMed | Google Scholar

Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, California 94305-5246, USA.

Find articles by Yang, Z. in: JCI | PubMed | Google Scholar

Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, California 94305-5246, USA.

Find articles by Schwartz, K. in: JCI | PubMed | Google Scholar

Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, California 94305-5246, USA.

Find articles by Zhang, J. in: JCI | PubMed | Google Scholar

Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, California 94305-5246, USA.

Find articles by Rubin, E. in: JCI | PubMed | Google Scholar

Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, California 94305-5246, USA.

Find articles by Lawn, R. in: JCI | PubMed | Google Scholar

Published August 1, 1997 - More info

Published in Volume 100, Issue 3 on August 1, 1997
J Clin Invest. 1997;100(3):558–564. https://doi.org/10.1172/JCI119565.
© 1997 The American Society for Clinical Investigation
Published August 1, 1997 - Version history
View PDF
Abstract

Lipoprotein(a) contributes to the development of atherosclerosis through the binding of its plasminogen-like apolipoprotein(a) component to fibrin and other plasminogen substrates. Apolipoprotein(a) contains a major lysine binding site in one of its kringle domains. Destruction of this site by mutagenesis greatly reduces the binding of apolipoprotein(a) to lysine and fibrin. Transgenic mice expressing this mutant form of apolipoprotein(a) as well as mice expressing wild-type apolipoprotein(a) have been created in an inbred mouse strain. The wild-type apolipoprotein(a) transgenic mice have a fivefold increase in the development of lipid lesions, as well as a large increase in the focal deposition of apolipoprotein(a) in the aorta, compared with the lysine binding site mutant strain and to nontransgenic littermates. The results demonstrate the key role of this lysine binding site in the pathogenic activity of apolipoprotein(a) in a murine model system.

Version history
  • Version 1 (August 1, 1997): No description
Advertisement
Advertisement